Bio


Eduardo J. Pérez-Guerrero, MD, is a third-year Internal Medicine resident and rising Chief Resident at Stanford University with clinical interests in cardiology and electrophysiology. His research centers on the intersection of wearable technology, artificial intelligence, and cardiovascular medicine, including work with the Apple Heart Study team. He is actively involved in the implementation and evaluation of AI-driven tools in clinical care, with a focus on assessing performance, safety, and real-world impact on patient outcomes.

Clinical Focus


  • Internal Medicine

Academic Appointments


  • Clinical Scholar, Medicine

All Publications


  • AI-Identified Reasons for Nonescalation of Lipid-Lowering Therapy for Secondary Prevention. JAMA cardiology Somani, S., Kim, D. D., Ramaraju, V., Ngo, S., Babu, C., Bouladian, S., Chen, T., King, S., Perez-Guerrero, E., Ronaghi, S., Hwang, J., Maron, D. J., Hernandez-Boussard, T., Alsentzer, E., Rodriguez, F. 2026

    Abstract

    Despite guideline recommendations for low-density lipoprotein cholesterol (LDL-C) goals in secondary prevention of atherosclerotic cardiovascular disease (ASCVD), lipid-lowering therapy (LLT) remains underused. Identifying treat-to-target strategy adoption and reasons for LLT nonescalation are critical to close guideline-discordant care gaps.To determine whether large language models (LLMs) can identify a treat-to-target strategy use and extract reasons for LLT nonescalation from clinical notes when LDL-C concentration is above goal.This was a retrospective cohort study of patients from January 1, 2019, through May 15, 2025. Notes from most recent clinical encounters were retrieved and split into development, test, and inference sets. The setting was a large, integrated health system in Northern California. Adults aged 18 to 90 years with 2 or more clinician-billed encounters for ASCVD and with LDL-C level greater than or equal to 70 mg/dL at the most recent encounter were included in note-based analyses.Documented LDL-C targets and LLT management decisions.Model performance was evaluated on LDL-C target documentation, LDL-C target value, LLT adjustment, and reasons for nonescalation against clinical annotations. Outcome prevalence was assessed on the inference set.A total of 28 113 unique patients with ASCVD-related encounters were identified, of whom 13 810 (49.1%; mean [SD] age, 70.9 [11.4] years; 7904 male [57.2%]) had above-goal LDL-C level. Model-annotator and interannotator reliability were not statistically different across outcomes, and micro-weighted F1 scores ranged from 0.80 to 0.98. Of the 13 394 patients with above-goal LDL-C level and 13 354 relevant notes in the inference set, a treat-to-target strategy was identified in 3756 (28.1%) of all relevant notes, most commonly targeting an LDL-C level less than 70 mg/dL (2280 [17.1%]). LLT was not escalated in 11 842 of all relevant notes (88.7%), with 4788 (40.4%) containing at least 1 LLT nonescalation reason, most often due to patient-reported adverse effects (1683 [12.6%]), LDL-C level close to goal (922 [6.9%]), patient preference to avoid LLT (914 [6.8%]), preference for lifestyle changes (811 [6.1%]), and deferral to repeat laboratory tests (617 [4.6%]).Results of this study show that after using a state-of-the art LLM, nearly 9 in 10 ASCVD encounters with above-goal LDL-C level did not have patient LLT escalated, most often because of adverse effects, patient preference, preference for lifestyle changes, therapeutic inertia (eg, repeat laboratory tests), and near-goal LDL-C level. These findings highlight an avenue for personalizing system-level digital health interventions to help discover and minimize guideline-discordant care gaps in secondary prevention of ASCVD.

    View details for DOI 10.1001/jamacardio.2026.5230

    View details for PubMedID 42998242

  • Operationalizing AI for Cardiovascular Care: An AI and Centralized Outreach-Enabled Workflow for Symptomatic Peripheral Artery Disease Detection Perez Guerrero, E., Jain, S. S., Banda, J., Shah, N. H., Weng, Y., Ross, E., Chen, J., Fukaya, E., Geronimo, R., Schechtman, A., McDonald, V., Villanea, R., Pfeffer, M., Truong, J., Pandya, A. LIPPINCOTT WILLIAMS & WILKINS. 2026: A8563
  • AI-Enabled Identification of Reasons for Non-Escalation of Lipid-Lowering Therapies in Patients with Atherosclerotic Cardiovascular Disease Somani, S., Kim, D. D., Ngo, S., Babu, C., Bouladian, S., Chen, T., King, S., Perez Guerrero, E., Ronaghi, S., Maron, D. J., Hernandez-Boussard, T., Alsentzer, E., Rodriguez, F. LIPPINCOTT WILLIAMS & WILKINS. 2026
  • Demographic Differences in Discussion of Lipid-Lowering Therapy in Atherosclerotic Cardiovascular Disease Patients with Above-Goal LDL-C Kim, D., Somani, S., Ngo, S., Babu, C., Bouladian, S., Chen, T., King, S., Perez Guerrero, E., Ronaghi, S., Maron, D. J., Hernandez-Boussard, T., Alsentzer, E., Rodriguez, F. LIPPINCOTT WILLIAMS & WILKINS. 2026: A14522
  • Artificial Intelligence in Heart Failure: From Earlier Disease Detection to Integrated Care Delivery. Journal of cardiac failure Pérez-Guerrero, E., Parsa, S., Eltahir, A. A., Segar, M. W., Oikonomou, E. K., Cheng, R. K., Sandhu, A. T., Pandey, A., Ouyang, D., Poterucha, T. J., Ahmad, F. S., Khera, R., Elias, P., Perez, M. V., Ashley, E. A., Jain, S. S. 2026; 32 (11): 1985-1998

    Abstract

    Artificial intelligence (AI) is increasingly positioned to improve heart failure (HF) care by predicting risk, enabling earlier disease identification, and supporting more reliable delivery of evidence-based management. Current applications span opportunistic detection for low ejection fraction, HF with preserved ejection fraction, and structural heart disease using tools such as AI-enabled electrocardiography, imaging- and electronic health record‒based risk stratification, clinician-facing decision support, remote medication titration, and wearable monitoring platforms. The strongest evidence suggests that AI is most effective when embedded into active clinical workflows that guide targeted testing, treatment optimization, and longitudinal follow-up, rather than functioning as passive alerts alone. This review examines the emerging landscape of AI-enabled HF care delivery from early detection through chronic management, with emphasis on implementation, workflow integration, and the capacity of these tools to improve diagnostic yield and ultimately scalability.

    View details for DOI 10.1016/j.cardfail.2026.08.033

    View details for PubMedID 43009252

  • Cardiovascular Diagnoses Following Smartwatch Irregular Pulse Notifications: Insights from the Apple Heart Study Perez Guerrero, E., Parsa, S., Gjermeni, D., Sakalaki, M., Alipour, P., Yu, K., Hedlin, H., Desai, M., Phillips, A., Russo, A., Granger, C., Kowey, P., Hills, M., Rumsfeld, J., Turakhia, M., Mahaffey, K., Perez, M. LIPPINCOTT WILLIAMS & WILKINS. 2025
  • Performance of Large Language Model-Generated Spanish Discharge Material. Journal of general internal medicine Pérez-Guerrero, E., Aali, A., Irizarry, E., Corso, N., Hom, J., Rodriguez, F., Santiago, C. 2025

    View details for DOI 10.1007/s11606-025-09758-2

    View details for PubMedID 40715961

  • AGE AND COMORBIDITIES ASSOCIATED WITH HEALTHCARE UTILIZATION AFTER RECEIVING A SMARTWATCH IRREGULAR PULSE NOTIFICATION SUGGESTIVE OF ATRIAL FIBRILLATION: FINDINGS FROM THE APPLE HEART STUDY Guerrero, E., Sakalaki, M., Yu, K., Hedlin, H., Mahaffey, K. W., Russo, A. M., Granger, C. B., Kowey, P. R., Desai, M., Hils, M., Philips, A., Rumsfeld, J. S., Turakhia, M., Perez, M. ELSEVIER SCIENCE INC. 2025: 2534
  • Understanding Reasons for Oral Anticoagulation Nonprescription in Atrial Fibrillation Using Large Language Models. Journal of the American Heart Association Somani, S., Kim, D. D., Perez-Guerrero, E., Ngo, S., Seto, T., Al-Kindi, S., Hernandez-Boussard, T., Rodriguez, F. 2025: e040419

    Abstract

    Rates of oral anticoagulation (OAC) nonprescription in atrial fibrillation approach 50%. Understanding reasons for OAC nonprescription may reduce gaps in guideline-recommended care. We aimed to identify reasons for OAC nonprescription from clinical notes using large language models.We identified all patients and associated clinical notes in our health care system with a clinician-billed visit for atrial fibrillation without another indication for OAC and stratified them on the basis of active OAC prescriptions. Three annotators labeled reasons for OAC nonprescription in clinical notes on 10% of all patients ("annotation set"). We engineered prompts for a generative large language model (Generative Pre-trained Transformer 4) and trained a discriminative large language model (ClinicalBERT) to identify reasons for OAC nonprescription and selected the best-performing model to predict reasons for the remaining 90% of patients ("inference set").A total of 35 737 patients were identified, of which 7712 (21.6%) did not have active OAC prescriptions. A total of 910 notes across 771 patients were annotated. Generative Pre-trained Transformer 4 outperformed ClinicalBERT (macro-F1 score across all reasons of 0.79, compared with 0.69 for ClinicalBERT). Using Generative Pre-trained Transformer 4 on the inference set, 61.1% of notes had documented reasons for OAC nonprescription, most commonly the alternative use of an antiplatelet agent (23.3%), therapeutic inertia (21.0%), and low burden of atrial fibrillation (17.1%).This is the first study using large language models to extract documented reasons for OAC nonprescription from clinical notes in patients with atrial fibrillation and reveals guideline-discordant practices and actionable insights for the development of health system interventions to reduce OAC nonprescription.

    View details for DOI 10.1161/JAHA.124.040419

    View details for PubMedID 40145287

  • Introduction to Wearable Technology in Arrhythmia Management. Heart rhythm Perez-Guerrero, E. J., Mehrotra, I., Jain, S. S., Perez, M. V. 2024

    View details for DOI 10.1016/j.hrthm.2024.07.098

    View details for PubMedID 39053750

  • Large Language Models as Partners in Medical Literature. Heart rhythm Perez-Guerrero, E. J., Mehrotra, I., Jain, S. S., Perez, M. V. 2024

    View details for DOI 10.1016/j.hrthm.2024.07.097

    View details for PubMedID 39053754

  • Who are we missing? Language exclusivity of patient-reported outcomes in atrial fibrillation clinical trials. Journal of cardiovascular electrophysiology Lan, R. H., Guerrero, E. P., Lewis, E. F., Wang, P. J. 2024

    Abstract

    Patient-reported outcomes (PROs) are increasingly used to evaluate quality of life (QoL) in Atrial Fibrillation (AF) patients, providing crucial insights in clinical trials. This study examines the frequency of PRO use in AF trials and the linguistic accessibility of AF-specific PROs.As the United States becomes more multilingual, ensuring PROs are available in various languages is vital. The number of people speaking a language other than English at home has tripled from 23.1 million in 1980 to 67.8 million in 2019. This diversity necessitates the availability of PROs in multiple languages for inclusive clinical assessments.We queried ClinicalTrials.gov for all US interventional AF trials up to November 28, 2023, reviewing each for PRO usage as primary or secondary outcomes. We identified the five most common AF-specific and generic PROs, extracting their available translations and original languages from published sources.Of 233 identified trials, 191 had associated publications, with 180 (94.2%) conducted solely in English. Only one trial (0.4%) used an AF-specific PRO as a primary outcome, compared to four (1.7%) with a generic PRO. Ten trials (4.3%) used AF-specific PROs as secondary endpoints, versus 22 (9.4%) using generic PROs. AF-specific PROs had significantly fewer translations than generic PROs (11.2 vs. 148.8; p < .001). The AF Effect on Quality-of-Life (AFEQT) was available in 24 languages, with limited translations in commonly spoken US languages like Arabic and Asian languages.The limited availability of AF-specific PRO translations highlights a barrier to inclusive AF clinical trials. Expanding translations for AF-specific PROs is crucial for equitable QoL assessments.

    View details for DOI 10.1111/jce.16360

    View details for PubMedID 38953220

  • Diversity in Atrial Fibrillation Trials: Assessing the Role of Language Proficiency as a Recruitment Barrier. Heart rhythm Lan, R. H., Guerrero, E. P., Shen, S., Qin, F., Ritter, V., Brown-Johnson, C., Clark, K., Rose, E., Lewis, E. F., Wang, P. J. 2024

    View details for DOI 10.1016/j.hrthm.2024.05.034

    View details for PubMedID 38777255

  • The Rising Trend in the Use of Patient-Reported Outcomes in Atrial Fibrillation Clinical Trials. Heart rhythm Lan, R. H., Perez-Guerrero, E., Saeed, M., Perez, M. V. 2024

    View details for DOI 10.1016/j.hrthm.2024.04.015

    View details for PubMedID 38604591